Acelyrin, Inc. (SLRN) Financials

SLRN Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 800.5 million 1.2 billion
June 30, 2023 835.1 million 34.1 million
March 31, 2023 298.5 million 298.5 million
Dec. 31, 2022 333.0 million 444.4 million

SLRN Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -39.3 million 15.3 million
June 30, 2023 -33.4 million 8.5 million
March 31, 2023 -35.6 million 7.1 million
Dec. 31, 2022 -18.1 million 1.5 million

SLRN Net Income

No data available :(

SLRN Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 788.4 million - 1.3 million
June 30, 2023 823.0 million - 1.3 million
March 31, 2023 289.2 million - 1.3 million
Dec. 31, 2022 326.1 million - -

SLRN Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 96.9 million
June 30, 2023 65.2 million
March 31, 2023 97.2 million
Dec. 31, 2022 97.2 million

SLRN Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 197000 74.6 million 19.9 million -
June 30, 2023 1.8 million 30.0 million 12.7 million -
March 31, 2023 10.2 million 167.9 million 11.9 million -
Dec. 31, 2022 - 192.4 million 15.9 million -

SLRN Cost of Revenue

No data available :(

SLRN

Price: $2.27

52 week price:
1.85
7.25

Earnings Per Share: -2.69 USD

P/E Ratio: -0.84

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Market Capitalization: 229.2 million

Links: